The Two Families Infectious Disease Tests Are Paid In Were Both Cut

There is no sheltered code family in this field

In the CMS preliminary CY 2027 fee schedule, molecular pathology codes fall 22 per cent and microbiology codes 19.3 per cent, phased at 15 per cent a year through 2029. Chemistry falls 16 per cent. Overall, 1,171 of 1,528 priced codes decline.

Every other discipline report in this cluster has a family it can shelter in. Clinical chemistry’s menu is largely chemistry-coded, so the 16 per cent reset is its exposure. Immunoassay’s high-value menu is spread across families that move differently. Haematology’s counts and coagulation sit in families outside the hardest tier.

Infectious disease diagnostics does not have that option, because its two growth businesses are paid in the two families being cut hardest. In our construction of the field, the molecular-coded segments — syndromic and multiplex panels at USD 6,300 million, viral load and treatment monitoring at USD 2,900 million, metagenomic identification at USD 420 million — total USD 9,620 million, or 31.91 per cent of the base. Add laboratory microbiology, the culture business that microbiology codes pay for, and the two cut families cover USD 18,450 million — 61.19 per cent of the field.

Sixty-one per cent of this market is paid on schedules cut by roughly a fifth. There is no mix rotation available that avoids it, because both ends of the menu — the cheap high-volume end and the expensive molecular end — are in the cut.

The inversion: growth moved into the exposure

This is the part that reads badly for anyone who modelled the field on its 2020–2025 behaviour. When infectious disease diagnostics was a culture-and-serology business, its revenue sat in microbiology codes and grew slowly. When it became a panel business, its revenue moved into molecular pathology codes — and those are the steeper of the two cuts.

The mix effect that produced the growth is the same mix that produced the exposure. Across the field, constant-menu price runs at −2.10 per cent a year against a mix contribution of +1.49, netting −0.61 on revenue per test. Panelisation is doing all the work: without it, a field with flat volume and falling administered price would be shrinking. With it, the field grows 4.85 per cent — but every point of that mix gain raises the share of revenue sitting in the 22 per cent family.

Stated plainly: the field’s growth engine and its price risk are the same variable, and it is now two-thirds loaded.

What a 15 per cent a year phase-in actually does

The phase-in is real relief and it is often described as if it were forgiveness. It is not. A 22 per cent reduction phased at 15 per cent a year completes in three years, and during those years the base is not static — volume keeps growing, so the cut applies to a rising number of tests each year. The deferred portion is not cancelled, it is paid later, and the later payment lands on a larger base.

The offsetting consideration is equally real: a phased cut lets a vendor reprice contracts as they renew rather than absorb the whole reduction against an existing book. Where a health system procures on multi-year tenders, the phase-in period and the contract cycle interact, and which one finishes first determines who carries the difference. That is a contract-level question, and it is why our 24 open-ended interviews were conducted around tender cycles rather than around product lines.

Who absorbs it, in order of likelihood

Three absorbers, and the field will use all three.

The laboratory absorbs first, because it is the residual claimant. A laboratory that cannot raise its price for a panel cuts the menu instead — dropping the low-yield assay, batching the run, sending the test out. In a fragmented field with no vendor large enough to defend a code, this is the default path, and it shows up as slower volume rather than as a price headline.

The vendor absorbs second, through discount. This is where fragmentation becomes visible in the P&L: with no share leader, no participant has the pricing power to hold a tender at the old rate, so the reduction is competed rather than negotiated. That is why the fee-cut scenario in our model lands at 4.02 per cent rather than at the base case — the cut is assumed to pass through rather than be absorbed by margin alone.

The menu absorbs third: the field rotates toward whatever is newly reimbursable. Metagenomic identification at 14.02 per cent is exactly that bet, and it is a bet on a code family that is itself being cut. Recovery by menu is available; escape by menu is not.

What would make this benign

One thing, and it is observable: whether syndromic panels settle at a single national price per episode rather than per-analyte rates. Per-analyte pricing is what makes a 22 per cent code cut devastating to a 20-target panel — the cut multiplies by the number of analytes. A per-episode price converts the same clinical work into a single payment that a cut reduces once. Laboratories and vendors both have an interest in that outcome, which is the rare case in this field where their interests align.

Until then, the arithmetic stands: this is the one application area in diagnostics with no sheltered code family, and its exposure rose as its growth rose.

Method and what we do not claim

The fee-schedule figures are from the CMS preliminary CY 2027 fact sheet and are preliminary; the final rule can moderate them, and if it does, the exposure described here narrows in absolute terms without changing in structure. Our mapping of segments to code families is our construction, not an official crosswalk, and is stated as such in the report. The mechanism by which laboratories drop a menu line before they renegotiate a contract comes from 38 depth interviews across 11 markets, 24 open-ended tender-cycle interviews, a 171-respondent survey and four conferences; it carries no figure.

The code-by-code detail for the microbiology family is in Medicare Cut 224 Microbiology Codes by 19.3 Per Cent. The price-per-test mechanism that panelisation is producing across all disciplines is in Microbiology Is the Only Discipline in Diagnostics Where the Price of a Test Is Rising, and the field’s structural fragmentation in The Largest Application Area in Diagnostics Has No Leader.

Companion reading

Three other pieces sit on the same construction. The Largest Application Area in Diagnostics Has No Leader explains why nobody in this field is large enough to defend a code, which is the mechanism behind the pass-through modelled here. The Largest Risk to Infectious Disease Diagnostics Is a Budget Line, Not a Competitor prices the other downside scenario and shows it is worth 138 basis points of growth. The Pandemic Built the Point-of-Care Channel and the Channel Is Now Repricing covers the one route out of a molecular-lab price — a waived test — and why it inherits the same cut.